Back to today’s briefing

Story perspectives

Chiesi and Arbor Invest $115 Million in CRISPR Treatment

10/11/2025

32 7

Summary

Story summary

Chiesi Group (Italy-based) and Arbor Biotechnologies launched a collaboration with a $115 million investment.
The focus is ABO-101, a potential one-time treatment for primary hyperoxaluria type 1 (PH1) that causes kidney damage from oxalate (PH1).
ABO-101 uses in vivo CRISPR gene editing to provide a lasting solution.
The parties emphasize urgency in advancing clinical trials and Arbor may receive up to $2 billion in milestone payments.

1 of 1

Story summary

Chiesi Group (Italy-based) and Arbor Biotechnologies launched a collaboration with a $115 million investment.
The focus is ABO-101, a potential one-time treatment for primary hyperoxaluria type 1 (PH1) that causes kidney damage from oxalate (PH1).
ABO-101 uses in vivo CRISPR gene editing to provide a lasting solution.
The parties emphasize urgency in advancing clinical trials and Arbor may receive up to $2 billion in milestone payments.